Stowers A W, Miller L H
Malaria Vaccine Development Unit, Laboratory of Parasitic Diseases, National Institute of Allergy and Infections Diseases, National Institutes of Health, Rockville, MD 20852, USA.
Trends Parasitol. 2001 Sep;17(9):415-9. doi: 10.1016/s1471-4922(01)02011-6.
The development of malaria blood-stage vaccines is gathering momentum: there are several new funding initiatives, one multiantigen formulation is currently being tested and at least one other blood-stage vaccine is expected to begin trials in 2001. However, there is no consensus over the best way to select which form of an antigen to take into clinical testing. There is thus a danger that less-effective vaccines might be tested in the field in the order of their availability, rather than merit. Here, we argue that first proving efficacy in the New World monkey challenge model would accelerate development.
有多项新的资金投入计划,一种多抗原制剂正在进行测试,预计至少还有一种血液阶段疫苗将于2001年开始试验。然而,对于选择哪种抗原形式进行临床试验的最佳方法尚无共识。因此,存在一种风险,即效果较差的疫苗可能会按照其可得性而非价值顺序在实地进行测试。在此,我们认为首先在新大陆猴挑战模型中证明疗效将加速研发进程。